NCT00116909已完成2 期
A Phase II Study of Single-Agent OSI-7904L in Patients With Locally Advanced or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Have Failed First-Line Therapy
OSI Pharmaceuticals8 个研究点 分布在 1 个国家目标入组 85 人开始时间: 2004年8月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 85
- 试验地点
- 8
研究概览
简要总结
Multi-center, Phase II study to evaluate the efficacy and safety of OSI-7904Lin head and neck cancer in patients who have failed first-line therapy
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed metastatic or locally recurrent SCCHN that is incurable with surgery or radiation therapy ECOG performance status 0-2 No more tha 1 prior chemotharapy regimen for metastatic or locally recurrent disease Adequate bone marrow, Hepatic and renal function. At least one target lesion greater than or equal to 20 mm.
排除标准
- •Symptomatic brain metasteses which are not stable, are not adequately controlled, are potenially life threatening or required radiation in the last 28 days Pregnant or lactating women. Concurrent anticancer therapy or other investigational drugs Patients with active or uncontrolled infections or other serious illnesses or medical conditions.
研究者
研究点 (8)
Loading locations...
相似试验
已完成
2 期
Phase II Study of Single Agent OSI-7904L in Patients With Gastric or Gastroesophageal (GEJ) CancerGastroesophageal AdenocarcinomaGastric AdenocarcinomaNCT00073502OSI Pharmaceuticals43
Unknown
2 期
Clinical Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy for Operable Locally Advanced Head and Neck Squamous Cell CarcinomaHead and Neck CancerSquamous Cell CarcinomaNCT04922450Hunan Cancer Hospital53
已完成
2 期
A Study of OSI-7904L Versus 5-FU/LV as Treatment in Patients With Biliary Tract CancerLocally Advanced or Metastatic Adenoca of the Biliary TractNCT00088270OSI Pharmaceuticals58
已完成
2 期
A Study to Evaluate Erlotinib in Patients With Advanced or Metastatic Breast Cancer During or Following ChemotherapyBreast CancerNCT00109265Genentech, Inc.
已完成
2 期
Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCCRecurrent Head and Neck Squamous Cell CarcinomaMetastatic Head and Neck Squamous Cell CarcinomaNCT05156970Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University81